KalVista is a research-led pharmaceutical company led by CEO Andrew Crockett that develops and patents selective and potent plasma kallikrein inhibitors designed for different routes of administration. Its most advanced program is an intravitreally administered plasma kallikrein inhibitor that completed a first-in-human study and is planned to enter Phase 2 in 2016 for diabetic macular edema (DME). The company is also advancing orally delivered plasma kallikrein inhibitors through preclinical testing for indications including hereditary angioedema (HAE). KalVista intends to use the new funding to advance its proprietary portfolio for DME and HAE. The company has offices in Porton Down, UK and an office in Boston, MA, USA. To date it has raised more than $57m in total financings. KalVista Pharmaceuticals is a newly formed ophthalmology company based in Southampton, UK, focused on developing novel plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME). The company acquired these inhibitors and all relevant intellectual property from Vantia Therapeutics and includes Vantia's former discovery group in its team. KalVista reports an advanced pre-clinical product pipeline and is targeting both intravitreal injection and oral administration routes. Founders include Dr Lloyd Paul Aiello and Dr Edward Feener, both affiliated with Harvard Medical School and the Joslin Diabetes Center. The management team is led by CEO Andrew Crockett. Financially, KalVista completed a £8m Series A funding round to support its development efforts.

Total raised

$46M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2015